News | November 28, 2024
Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Emcure has launched an awareness campaign to help spread the word about male anemia
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Subscribe To Our Newsletter & Stay Updated
